Loading...
XSHG600420
Market cap2.03bUSD
Jan 09, Last price  
11.10CNY
1D
-2.20%
1Q
-7.04%
Jan 2017
-32.97%
Name

Shanghai Shyndec Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XSHG:600420 chart
P/E
21.52
P/S
1.25
EPS
0.52
Div Yield, %
1.27%
Shrs. gr., 5y
3.12%
Rev. gr., 5y
1.06%
Revenues
11.93b
-7.93%
358,531,918502,746,161545,870,580624,322,933687,231,9331,164,233,7281,422,963,6451,702,623,2752,006,892,2342,349,747,9942,748,835,6682,682,244,6909,125,774,7738,517,753,72611,320,781,39312,199,106,72512,556,281,59513,944,948,27012,959,320,53311,931,810,343
Net income
692m
-20.24%
36,830,12158,686,12150,497,72894,029,95853,914,13789,052,252108,111,439120,032,511115,944,722132,787,532189,991,042221,052,732476,933,718515,802,593705,521,698928,467,067900,046,866821,145,853867,484,979691,880,495
CFO
1.72b
-39.76%
17,016,39357,898,13273,595,32782,308,03658,044,42597,434,742115,105,986136,123,080193,411,432207,496,007258,514,766226,646,450838,576,8382,314,541,6561,669,140,5751,270,137,2121,560,179,0111,679,662,3932,855,633,1051,720,373,788
Dividend
Sep 20, 20240.1 CNY/sh
Earnings
May 28, 2025

Profile

Shanghai Shyndec Pharmaceutical Co., Ltd. manufactures drug preparation products in China and internationally. It focuses on anti-infection, cardiovascular and cerebrovascular, anti-tumor, metabolism, and endocrine areas. The company was founded in 1996 and is based in Shanghai, China.
URL
http://www.shyndec.com/
IPO date
Jun 16, 2004
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
11,931,810
-7.93%
12,959,321
-7.07%
Cost of revenue
10,105,252
11,417,539
Unusual Expense (Income)
NOPBT
1,826,559
1,541,782
NOPBT Margin
15.31%
11.90%
Operating Taxes
131,949
116,635
Tax Rate
7.22%
7.56%
NOPAT
1,694,610
1,425,147
Net income
691,880
-20.24%
867,485
5.64%
Dividends
(189,355)
(102,698)
Dividend yield
1.52%
0.98%
Proceeds from repurchase of equity
1,188,000
BB yield
-11.29%
Debt
Debt current
45,048
379,373
Long-term debt
1,146,889
3,092,562
Deferred revenue
122,802
138,006
Other long-term liabilities
518
571
Net debt
(5,218,145)
(3,116,755)
Cash flow
Cash from operating activities
1,720,374
2,855,633
CAPEX
(357,194)
Cash from investing activities
(1,389,079)
Cash from financing activities
(1,093,390)
FCF
2,551,531
1,715,376
Balance
Cash
5,972,611
6,148,196
Long term investments
437,471
440,493
Excess cash
5,813,492
5,940,723
Stockholders' equity
8,697,400
8,574,837
Invested Capital
9,782,014
9,603,491
ROIC
17.48%
14.61%
ROCE
11.70%
9.84%
EV
Common stock shares outstanding
1,273,478
1,156,373
Price
9.79
7.58%
9.10
-12.25%
Market cap
12,467,348
18.48%
10,522,993
-13.84%
EV
9,199,055
9,253,515
EBITDA
2,645,444
2,384,270
EV/EBITDA
3.48
3.88
Interest
57,884
107,310
Interest/NOPBT
3.17%
6.96%